EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study

Chase Peng Yun Ng, Alexander Light iD, Charis Eleftheriou, Oliver Hug, Ellie Richardson, Tarra Gill-Taylor, Altaf Shamsuddin, Hamid Abboudi, Sachin Agrawal

BJUI Compass · 2025-07 · 6 (7)

DOI: 10.1002/bco2.70052 ↗

At a glance

Journal article in BJUI Compass, published online on 2025-07-17. Written by Chase Peng Yun Ng and 8 co-authors. Institution: Imperial Urology Imperial College Healthcare NHS Trust London UK. Cited 6 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research, Rosetrees Trust, Urology Foundation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Elderly and comorbid patients with non‐muscle invasive bladder cancer (NMIBC) often undergo repeated transurethral resection of bladder tumour (TURBT) under general anaesthesia. Transurethral laser ablation (TULA) is an outpatient‐based alternative with lower morbidity, cost and carbon footprint, but its long‐term efficacy is not well‐established. We report the long‐term outcomes of recurrent NMIBC treated with TULA, stratified by European Organisation for Research and Treatment of Cancer (EORTC) risk groups. Materials and Methods We conducted a single‐centre, retrospective cohort study, including all consecutive NMIBC patients treated with TULA between 2012 and 2023. The primary outcomes were recurrence‐free survival (RFS) and progression‐free survival (PFS) and secondary outcomes included cancer‐specific survival (CSS), overall survival (OS) and complications, stratified by EORTC risk groups. Data were analysed using Kaplan–Meier survival analysis and Cox regression model.

Results

Three hundred and nineteen patients (1186 TULAs), with a median age of 77 and median Charleson Comorbidity Index of 7, were included. Median follow up was 4.4 years. The 5‐year RFS of intermediate‐risk and high‐risk NMIBC treated with TULA were 31.8% (95%CI:25.6–39.7%) and 29.0% (95%CI: 20.1–42.0%), respectively, with no significant difference (p:0.47). The 5‐year PFS were 86.8% (95%CI: 82.1–91.7%) and 93.1% (95%CI: 85.2–100.0%), respectively. Overall, the 10‐year OS and CSS were 50.7% (95% CI: 41.8–61.5%) and 96.1% (95%CI: 93.3–98.9%), respectively. The complication rate was 4.0%. Age was the only positive predictor of recurrence. Limitations include missing data (7.9%) and single‐centre retrospective design.

Conclusion

TULA is a safe, minimally invasive treatment with long‐term efficacy for elderly and comorbid patients with recurrent NMIBC. Although recurrence rate at 5 years were high, progression rate, especially muscle invasion, was low and reassuring. Long‐term overall survival and cancer‐specific survival remained excellent.

Subjects

Author keywords

ablationbladder tumourlaserlong termnon‐muscle‐invasive bladder cancerprogressionrecurrencesurvival

Authors and institutions

  • Imperial Urology Imperial College Healthcare NHS Trust London UK.
  • Department of Surgery and Cancer Imperial College London London UK.
  • Department of Urology Ashford and St Peter's Hospital NHS Trust Ashford UK.

ORCID profiles: Alexander Light

Funding

  • National Institute for Health and Care Research
  • Rosetrees Trust
  • Urology Foundation

Cite

APA

Ng, C. P. Y., Light, A., Eleftheriou, C., Hug, O., Richardson, E., Gill-Taylor, T., Shamsuddin, A., Abboudi, H., & Agrawal, S. (2025). Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study. BJUI Compass, 6(7). https://doi.org/10.1002/bco2.70052

Vancouver

Ng CPY, Light A, Eleftheriou C, Hug O, Richardson E, Gill-Taylor T, et al. Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study. BJUI Compass. 2025;6(7). doi:10.1002/bco2.70052

BibTeX
@article{Ng2025,
  author = {Ng, Chase Peng Yun and Light, Alexander and Eleftheriou, Charis and Hug, Oliver and Richardson, Ellie and Gill-Taylor, Tarra and Shamsuddin, Altaf and Abboudi, Hamid and Agrawal, Sachin},
  title = {Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study},
  journal = {BJUI Compass},
  year = {2025},
  volume = {6},
  number = {7},
  doi = {10.1002/bco2.70052}
}
Start for free →